Robert Marcus
Stock Analyst at JP Morgan
(1.37)
# 3,391
Out of 4,863 analysts
21
Total ratings
47.06%
Success rate
-2.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PEN Penumbra | Maintains: Overweight | $230 → $285 | $260.97 | +9.21% | 3 | Feb 19, 2025 | |
| IART Integra LifeSciences Holdings | Upgrades: Neutral | $75 | $12.39 | +505.33% | 2 | Dec 17, 2021 | |
| BDX Becton, Dickinson and Company | Downgrades: Neutral | $265 | $172.10 | +53.98% | 10 | Aug 6, 2021 | |
| GKOS Glaukos | Downgrades: Underweight | $50 | $100.14 | -50.07% | 2 | Oct 8, 2020 | |
| TMDX TransMedics Group | Downgrades: Neutral | $15 | $141.96 | -89.43% | 2 | Oct 8, 2020 | |
| ATRC AtriCure | Maintains: Overweight | $48 → $57 | $32.31 | +76.42% | 2 | Jul 29, 2020 |
Penumbra
Feb 19, 2025
Maintains: Overweight
Price Target: $230 → $285
Current: $260.97
Upside: +9.21%
Integra LifeSciences Holdings
Dec 17, 2021
Upgrades: Neutral
Price Target: $75
Current: $12.39
Upside: +505.33%
Becton, Dickinson and Company
Aug 6, 2021
Downgrades: Neutral
Price Target: $265
Current: $172.10
Upside: +53.98%
Glaukos
Oct 8, 2020
Downgrades: Underweight
Price Target: $50
Current: $100.14
Upside: -50.07%
TransMedics Group
Oct 8, 2020
Downgrades: Neutral
Price Target: $15
Current: $141.96
Upside: -89.43%
AtriCure
Jul 29, 2020
Maintains: Overweight
Price Target: $48 → $57
Current: $32.31
Upside: +76.42%